AU2020903577A0 - Treatment of Optic Atrophy - Google Patents
Treatment of Optic AtrophyInfo
- Publication number
- AU2020903577A0 AU2020903577A0 AU2020903577A AU2020903577A AU2020903577A0 AU 2020903577 A0 AU2020903577 A0 AU 2020903577A0 AU 2020903577 A AU2020903577 A AU 2020903577A AU 2020903577 A AU2020903577 A AU 2020903577A AU 2020903577 A0 AU2020903577 A0 AU 2020903577A0
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- optic atrophy
- atrophy
- optic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001749 Optic Atrophy Diseases 0.000 title 1
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/026,388 US20230407310A1 (en) | 2020-10-02 | 2021-10-01 | Treatment of optic atrophy |
IL301506A IL301506A (en) | 2020-10-02 | 2021-10-01 | Treatment of optic atrophy |
PCT/AU2021/051154 WO2022067398A1 (en) | 2020-10-02 | 2021-10-01 | Treatment of optic atrophy |
JP2023519820A JP2023543494A (en) | 2020-10-02 | 2021-10-01 | Treatment of optic atrophy |
CA3193706A CA3193706A1 (en) | 2020-10-02 | 2021-10-01 | Treatment of optic atrophy |
KR1020237010649A KR20230076823A (en) | 2020-10-02 | 2021-10-01 | Treatment of optic nerve atrophy |
AU2021354152A AU2021354152A1 (en) | 2020-10-02 | 2021-10-01 | Treatment of optic atrophy |
CN202180067382.8A CN116322708A (en) | 2020-10-02 | 2021-10-01 | Treatment of optic atrophy |
EP21873742.7A EP4222265A1 (en) | 2020-10-02 | 2021-10-01 | Treatment of optic atrophy |
BR112023005748A BR112023005748A2 (en) | 2020-10-02 | 2021-10-01 | OPTIC ATROPHY TREATMENT |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2020903577A0 true AU2020903577A0 (en) | 2020-10-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4132507A4 (en) | Methods of treatment of coronavirus-induced inflammation conditions | |
EP4149451A4 (en) | Cysteamine for the treatment of sars-cov-2 infection | |
EP4096653A4 (en) | Compositions for the treatment of angiolipoma | |
AU2020903577A0 (en) | Treatment of Optic Atrophy | |
EP4132503A4 (en) | Methods for treatment of coronavirus infections | |
EP4065106A4 (en) | Methods of treating hiv-1 infection | |
EP4097297A4 (en) | Treatment of bacterial nanocellulose | |
AU2022900163A0 (en) | Method Of Treatment for Optic Atrophy | |
AU2021900740A0 (en) | Combination Methods of Treatment | |
AU2021903030A0 (en) | Methods of treatment | |
AU2021902512A0 (en) | Methods of treatment | |
AU2021900789A0 (en) | Methods of treatment | |
AU2020903332A0 (en) | Methods of treatment | |
EP4135719A4 (en) | Treatment of coronavirus infections | |
AU2020902585A0 (en) | Methods of treatment | |
AU2023902382A0 (en) | Methods of treatment | |
AU2020900580A0 (en) | Methods of Treatment | |
AU2021903789A0 (en) | Methods of treating sars-cov-2 infection | |
AU2020901711A0 (en) | Treatment of coronavirus | |
EP4087556A4 (en) | Methods for treatment of damaged biliary ducts | |
AU2021902405A0 (en) | Method of treatment | |
AU2021900204A0 (en) | Method of treatment | |
EP4103200A4 (en) | Method of treatment using meta-arsenite | |
AU2020900433A0 (en) | Method of treatment | |
AU2020900220A0 (en) | Method of Treatment |